Anemia management in CKD; what is the Hgb target to balance cardiovascular risk?

• A. Normalize to 15 g/dL
• B. Target around 10-11 g/dL; avoid overcorrection to reduce CV risk
• C. Aim for 8 g/dL
• D. No target recommended

Answer: (B)

Balancing benefits of treating anemia in CKD with cardiovascular risk requires targeting a modest hemoglobin level rather than normalizing it. Raising hemoglobin to about 10-11 g/dL with erythropoiesis-stimulating agents can reduce symptoms and the need for transfusions without increasing cardiovascular danger. Pushing hemoglobin toward normal levels (around 15 g/dL) has been linked to higher rates of hypertension, thromboembolism, stroke, and even death in CKD patients, so avoid overcorrection. If hemoglobin trends toward or above 11 g/dL, adjust or reduce ESA dosing and reassess iron status and inflammation. The aim is a safe, symptom-relieving target rather than full normalization, which is why a around-10 to 11 g/dL target is preferred.